Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safimaltib - Janssen Research & Development

Next Previous
Drug Profile

Safimaltib - Janssen Research & Development

Alternative Names: JNJ-6633; JNJ-67856633

Latest Information Update: 03 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Research & Development
  • Class Antineoplastics; Small molecules
  • Mechanism of Action MALT1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • No development reported Diffuse large B cell lymphoma

Most Recent Events

  • 22 May 2025 Janssen Research & Development completes the Phase-I clinical trials in Chronic lymphocytic leukaemia (Second-line therapy or greater) in United Kingdom, Australia, Spain, South Korea, Japan, Israel, Greece, Italy, France, Germany, China, USA (PO) (NCT03900598)
  • 22 May 2025 Janssen Research & Development completes the Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in United Kingdom, Australia, Spain, South Korea, Japan, Israel, Greece, Italy, France, Germany, China, USA (PO) (NCT03900598)
  • 10 Apr 2025 Phase I trial for Chronic-lymphocytic-leukaemia(Combination therapy) and Non-Hodgkin's lymphoma (Combination therapy) is ongoing in France (PO) (NCT04657224) (EudraCT 2020-003149-12)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top